Seeking Alpha

More on Boston Scientific's (BSX) Q2: EPS doubles analysts' estimates and revenue comes in above...

More on Boston Scientific's (BSX) Q2: EPS doubles analysts' estimates and revenue comes in above the high end of guidance even as sales fall on a Y/Y basis (+2% on a constant currency basis). Revenue growth (as reported) by segment: Interventional Cardiology, -5%; Peripheral Interventions, +2%; Cardiovascular, -4%, Cardiac Rhythm, -3%; Electrophysiology, -3%; Rhythm Management, -3%, Endoscopy, +5%, Urology/ Women's Health, -1%; Neuromodulation, +21%; MedSurg, +6%. Outlook: Q3 and FY EPS of $0.14-0.16 and $0.67-0.71 respectively on sales of $1.7-1.76B next quarter and $7.05-7.17B for the full year. Shares +9% premarket. (PR)

Check out Seeking Alpha’s new Earnings Center »

Comments (1)
  • TA_Junkie
    , contributor
    Comments (26) | Send Message
     
    One of the most bullish charts among SP500 and a great turn around!
    25 Jul 2013, 11:59 AM Reply Like
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs